{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:09:17Z","timestamp":1776532157280,"version":"3.51.2"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Health Service Research Scotland Senior Fellowship"},{"DOI":"10.13039\/501100000589","name":"Chief Scientist Office","doi-asserted-by":"publisher","award":["ETM\/285"],"award-info":[{"award-number":["ETM\/285"]}],"id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","award":["MPG16-7"],"award-info":[{"award-number":["MPG16-7"]}],"id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DJM"},{"name":"Chief Scientist Office and British Lung Foundation","award":["APHD-13-5"],"award-info":[{"award-number":["APHD-13-5"]}]},{"name":"Chief Scientist Office and British Lung Foundation","award":["CSOBLFRG16-2"],"award-info":[{"award-number":["CSOBLFRG16-2"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.rmed.2017.11.015","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T17:15:15Z","timestamp":1511716515000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Progress and challenges in Mesothelioma: From bench to bedside"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-6641","authenticated-orcid":false,"given":"Kevin G.","family":"Blyth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2017.11.015_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0003-4878(00)00045-4","article-title":"The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure","volume":"44","author":"Hodgson","year":"2000","journal-title":"Ann. Occup. Hyg."},{"key":"10.1016\/j.rmed.2017.11.015_bib2","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0169-5002(14)70076-5","article-title":"76 Early experience of a regional mesothelioma MDT in the West of Scotland","volume":"83","author":"Tsim","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the national lung cancer audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejrad.2008.02.004","article-title":"Malignant pleural mesothelioma: computed tomography and correlation with histology","volume":"70","author":"Seely","year":"2009","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.rmed.2017.11.015_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/thoraxjnl-2014-206054","article-title":"Role of CT in assessing pleural malignancy prior to thoracoscopy","volume":"70","author":"Hallifax","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2017.11.015_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.11.010","article-title":"The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy","volume":"103","author":"Tsim","year":"2017","journal-title":"Lung Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2017.11.015_bib7","doi-asserted-by":"crossref","first-page":"ii4","DOI":"10.1136\/thx.2010.136978","article-title":"BTS pleural guideline group, investigation of a unilateral pleural effusion in adults: british thoracic society pleural disease guideline 2010","volume":"65","author":"Hooper","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2017.11.015_bib8","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","article-title":"Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial","volume":"361","author":"Maskell","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.11.015_bib9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/JTO.0b013e3181c0a7ff","article-title":"Clinical value of fluorodeoxyglucose-positron emission tomography\/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study","volume":"4","author":"Yildirim","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1378\/chest.14-0820","article-title":"Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis","volume":"147","author":"Porcel","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.11.015_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.acra.2013.09.015","article-title":"Diagnostic accuracy of 18F-FDG-PET and PET\/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis","volume":"21","author":"Treglia","year":"2014","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.rmed.2017.11.015_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/RLI.0b013e3181817b3d","article-title":"Computed tomography, positron emission tomography, positron emission tomography\/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results","volume":"43","author":"Plathow","year":"2008","journal-title":"Investig. Radiol."},{"key":"10.1016\/j.rmed.2017.11.015_bib13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jtcvs.2004.10.034","article-title":"Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications","volume":"129","author":"Erasmus","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.rmed.2017.11.015_bib14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejcts.2008.07.050","article-title":"Nordic Mesothelioma Group, Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy","volume":"34","author":"S\u00f8rensen","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.rmed.2017.11.015_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.athoracsur.2004.01.034","article-title":"The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma","volume":"78","author":"Stewart","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.rmed.2017.11.015_bib16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1080\/0284186X.2016.1234066","article-title":"Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study","volume":"55","author":"Botticella","year":"2016","journal-title":"Acta Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2016.09.003","article-title":"Imaging in pleural mesothelioma: a review of the 13th international conference of the international mesothelioma interest group","volume":"101","author":"Armato","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European respiratory society and the European society of thoracic surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2017.11.015_bib19","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1136\/thx.2010.137018","article-title":"Local anaesthetic thoracoscopy: British thoracic society pleural disease guideline 2010","volume":"65","author":"Rahman","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2017.11.015_bib20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1378\/chest.14-0299","article-title":"Physician-based ultrasound-guided biopsy for diagnosing pleural disease","volume":"146","author":"Hallifax","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.11.015_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/dc.23271","volume":"43","author":"Hjerpe","year":"2015","journal-title":"Diagn. Cytopathol."},{"key":"10.1016\/j.rmed.2017.11.015_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.rmed.2017.11.015_bib23","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/cas.12769","article-title":"Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue","volume":"106","author":"Hida","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.rmed.2017.11.015_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol. Int."},{"key":"10.1016\/j.rmed.2017.11.015_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.rmed.2017.11.015_bib26","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib27","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2017.11.015_bib28","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib29","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2017.11.015_bib30","doi-asserted-by":"crossref","first-page":"e013324","DOI":"10.1136\/bmjopen-2016-013324","article-title":"Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study","volume":"6","author":"Tsim","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmed.2017.11.015_bib31","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.11.015_bib32","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC mesothelioma staging project: improving staging of a rare disease through international participation","volume":"11","author":"Pass","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib33","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the T Descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib34","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the N Descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib35","article-title":"Lymphatic drainage of the pleura and its effect on tumor metastasis and spread","volume":"3","author":"Bilgi","year":"2009","journal-title":"T\u00fcrk Toraks Derne\u011fi Plevra B\u00fclteni"},{"key":"10.1016\/j.rmed.2017.11.015_bib36","first-page":"34","article-title":"Lymphatic drainage of intertracheobronchial lymph nodes. An anatomical study by injecting diaphragmatic pleura of foetuses and adult cadavers","volume":"23","author":"Okiemy","year":"2007","journal-title":"Le. Mali. Med."},{"key":"10.1016\/j.rmed.2017.11.015_bib37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.athoracsur.2008.04.012","article-title":"Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma","volume":"86","author":"Abdel Rahman","year":"2008","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.rmed.2017.11.015_bib38","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib39","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2012.5535","article-title":"Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial","volume":"307","author":"Davies","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.rmed.2017.11.015_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thoraxjnl-2012-203043","article-title":"Pleurodesis outcome in malignant pleural mesothelioma","volume":"68","author":"Fysh","year":"2013","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2017.11.015_bib41","doi-asserted-by":"crossref","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","article-title":"BTS pleural disease guideline group, management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010","volume":"65","author":"Roberts","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2017.11.015_bib42","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1183\/09031936.00153611","article-title":"Population-based survival for malignant mesothelioma after introduction of novel chemotherapy","volume":"40","author":"Damhuis","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.11.015_bib45","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.11.015_bib46","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Hooper","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JTO.0b013e318283da3e","article-title":"Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma","volume":"8","author":"Lustgarten","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib48","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","article-title":"Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma","volume":"48","author":"Blayney","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib49","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.11.015_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, \u2026","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.11.015_bib52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the \u2026","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib53","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.rmed.2017.11.015_bib54","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"Rice","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib55","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.11.015_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ejcts\/ezx079","article-title":"Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study","volume":"52","author":"Marulli","year":"2017","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.rmed.2017.11.015_bib57","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2013.11.004","article-title":"Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review","volume":"83","author":"MacLeod","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib59","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JTO.0000000000000499","article-title":"Is radiotherapy useful for treating pain in Mesothelioma?: a phase II trial","volume":"10","author":"MacLeod","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/JTO.0b013e31827740f0","article-title":"Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"8","author":"Gomez","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib61","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a \u2026","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.11.015_bib62","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib63","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib64","article-title":"Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient derived xenografts and mesothelin as a biomarker of tumor response","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.rmed.2017.11.015_bib66","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib67","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/S1556-0864(16)30330-6","article-title":"208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): results from a phase 1b trial","volume":"11","author":"Jahan","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib68","series-title":"World Conference on Lung Cancer","article-title":"OA 02.01-randomized phase II study of anetumab ravtansine or vinorelbine in patients with malignant pleural mesothelioma","author":"Hasegawa","year":"2017"},{"key":"10.1016\/j.rmed.2017.11.015_bib69","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2217\/fon-2017-0234","article-title":"Is immunotherapy a viable option in treating mesothelioma?","volume":"13","author":"Dumoulin","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib70","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib71","article-title":"Immune checkpoint inhibition in malignant mesothelioma: does it have a future?","volume":"0","author":"Mansfield","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib72","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","article-title":"Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma","volume":"60","author":"Bograd","year":"2011","journal-title":"Cancer Immunol. Immunother. CII."},{"key":"10.1016\/j.rmed.2017.11.015_bib73","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N","article-title":"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma","volume":"74","author":"Boutin","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib74","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib75","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.rmed.2017.11.015_bib76","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated Interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.11.015_bib77","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2016-0008","article-title":"A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial","volume":"8","author":"Mayor","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.rmed.2017.11.015_bib79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u201cT4 immunotherapy\u201d of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.rmed.2017.11.015_bib80","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib81","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib82","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.jtho.2016.11.301","article-title":"OA13.02 phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis","volume":"12","author":"Kindler","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib83","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib84","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib85","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","article-title":"New therapeutic strategies for malignant pleural mesothelioma","volume":"123","author":"Bonelli","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.rmed.2017.11.015_bib86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-meso trial","author":"Grosso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib87","doi-asserted-by":"crossref","first-page":"16848","DOI":"10.18632\/oncotarget.4253","article-title":"Reactive oxygen species a double-edged sword for mesothelioma","volume":"6","author":"Benedetti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.rmed.2017.11.015_bib88","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","article-title":"Gene of the month: BAP1","volume":"69","author":"Wang","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.rmed.2017.11.015_bib89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/JTO.0000000000000466","article-title":"Recent insights emerging from malignant mesothelioma genome sequencing","volume":"10","author":"Carbone","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib90","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.rmed.2017.11.015_bib91","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Misaghi","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.rmed.2017.11.015_bib92","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molcel.2009.01.014","article-title":"Nonproteolytic functions of ubiquitin in cell signaling","volume":"33","author":"Chen","year":"2009","journal-title":"Mol. Cell."},{"key":"10.1016\/j.rmed.2017.11.015_bib93","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2016.03.013","article-title":"Emerging roles for Polycomb proteins in cancer","volume":"36","author":"Pasini","year":"2016","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.rmed.2017.11.015_bib94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30227","article-title":"The pathogenesis of mesothelioma","volume":"29","author":"Carbone","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib95","first-page":"511","article-title":"Codeletion of p15 and p16 in primary malignant mesothelioma","volume":"11","author":"Xio","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.rmed.2017.11.015_bib96","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.freeradbiomed.2015.05.002","article-title":"Malignant mesothelioma as an oxidative stress-induced cancer: an update","volume":"86","author":"Chew","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.rmed.2017.11.015_bib97","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib98","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ncb3111","article-title":"Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway","volume":"17","author":"Mo","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.rmed.2017.11.015_bib99","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1111\/febs.13534","article-title":"Evidence of cancer-promoting roles for AMPK and related kinases","volume":"282","author":"Monteverde","year":"2015","journal-title":"Febs J."},{"key":"10.1016\/j.rmed.2017.11.015_bib100","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1073\/pnas.0915033107","article-title":"Histone H3 lysine 36 methyltransferase Hypb\/Setd2 is required for embryonic vascular remodeling","volume":"107","author":"Hu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.rmed.2017.11.015_bib101","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2016.07.005","article-title":"Dual chromatin and cytoskeletal remodeling by SETD2","volume":"166","author":"Park","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.rmed.2017.11.015_bib102","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1126\/science.287.5459.1824","article-title":"DNA damage-induced activation of p53 by the checkpoint kinase Chk2","volume":"287","author":"Hirao","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.rmed.2017.11.015_bib103","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"p53 in survival, death and metabolic health: a lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.rmed.2017.11.015_bib104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2049-3002-2-17","article-title":"Mitochondrial reactive oxygen species and cancer","volume":"2","author":"Sullivan","year":"2014","journal-title":"Cancer Metab."},{"key":"10.1016\/j.rmed.2017.11.015_bib105","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.rmed.2017.11.015_bib106","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2006.10.010","article-title":"Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo","volume":"10","author":"Ringshausen","year":"2006","journal-title":"Cancer Cell."},{"key":"10.1016\/j.rmed.2017.11.015_bib107","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1634\/theoncologist.12-10-1215","article-title":"Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial an alpe-adria thoracic oncology multidisciplinary group study (ATOM 002)","volume":"12","author":"Fasola","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.rmed.2017.11.015_bib108","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/JTO.0b013e31819f2e0e","article-title":"Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure","volume":"4","author":"Roberts","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2017.11.015_bib109","article-title":"Estimating past inhalation exposure to asbestos: a tool for risk attribution and disease screening","author":"Cherrie","year":"2017","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"10.1016\/j.rmed.2017.11.015_bib110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12014-016-9103-3","article-title":"ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms","volume":"13","author":"Morr\u00e9","year":"2016","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.rmed.2017.11.015_bib111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2014.08.005","article-title":"Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort","volume":"86","author":"Robinson","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmed.2017.11.015_bib112","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.rmed.2017.11.015_bib113","first-page":"1005","article-title":"Chemoprevention of asbestos-linked cancers: a systematic review","volume":"32","author":"Neri","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.rmed.2017.11.015_bib114","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejcts.2010.01.057","article-title":"Outcome of patients with nonspecific pleuritis\/fibrosis on thoracoscopic pleural biopsies","volume":"38","author":"Davies","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.rmed.2017.11.015_bib115","doi-asserted-by":"crossref","first-page":"26750","DOI":"10.1074\/jbc.M116.753236","article-title":"Malignant pleural effusion and ascites induce epithelial-mesenchymal transition and cancer stem-like cell properties via the vascular endothelial growth factor (VEGF)\/Phosphatidylinositol 3-kinase (PI3K)\/Akt\/Mechanistic target of rapamycin (mTOR) pathway","volume":"291","author":"Yin","year":"2016","journal-title":"J. Biol. Chem."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117304006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117304006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:38:10Z","timestamp":1760614690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117304006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":115,"alternative-id":["S0954611117304006"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.11.015","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and challenges in Mesothelioma: From bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}